Roth Capital Affirms Stemline Therapeutics (STML) at 'Buy'; Strong Cash Position Noted Ahead of ASH
Tweet Send to a Friend
Roth Capital affirms Stemline Therapeutics (Nasdaq: STML) at Buy with a price target of $32 following Q3 results.Analyst Joseph Pantginis ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
